Inventor · disambiguated record
Yuya Kasahara
Also filed as: KASAHARA YUYA
6 granted patents·3 pending applications·1 citations·filing 2017–2022
66Inventor score
Files withUNIV OSAKA5AICHI MEDICAL UNIV1MITSUBISHI TANABE PHARMA CORP1NATIONAL UNIV CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM1UNIV KYOTO1
Top patents by PatentIndex Score
9 records- 0174US11261440B2Antisense oligonucleic acidUNIV OSAKA·Filed 2018·Granted Mar 1, 2022·1 cites·13 claims
- 0263US12104154B2Antisense oligonucleic acidUNIV OSAKA·Filed 2022·Granted Oct 1, 2024·0 cites·16 claims
- 0354US2024240176A1Prevention or treatment of myopathy using mir-33b inhibitorUNIV KYOTO·Filed 2022·Application pending·0 cites
- 0450US12071624B2Antisense oligonucleotide targeting ARL4C molecule, and nucleic acid drug using antisense oligonucleotideUNIV OSAKA·Filed 2019·Granted Aug 27, 2024·0 cites·13 claims
- 0549US2023159924A1Prevention or treatment of aneurysms using mir-33b inhibitorMITSUBISHI TANABE PHARMA CORP·Filed 2021·Application pending·0 cites
- 0648US11866705B2Small cell lung cancer therapeutic agent containing oligonucleotideUNIV OSAKA·Filed 2019·Granted Jan 9, 2024·0 cites·4 claims
- 0748US2022282248A1Molecular targeted nucleic acid medicine for gastric cancerNATIONAL UNIV CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM·Filed 2020·Application pending·0 cites
- 0845US11479773B2Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfateAICHI MEDICAL UNIV·Filed 2018·Granted Oct 25, 2022·0 cites·15 claims
- 0935US11234995B2α-synuclein expression inhibitorUNIV OSAKA·Filed 2017·Granted Feb 1, 2022·0 cites·13 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →